Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
7.54
+0.13 (1.75%)
Nov 4, 2024, 4:00 PM EST - Market closed
Adverum Biotechnologies Employees
Adverum Biotechnologies had 121 employees as of December 31, 2023. The number of employees decreased by 2 or -1.63% compared to the previous year.
Employees
121
Change (1Y)
-2
Growth (1Y)
-1.63%
Revenue / Employee
$8,264
Profits / Employee
-$777,777
Market Cap
156.84M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Tenaya Therapeutics | 140 |
Alpha Tau Medical | 121 |
Lineage Cell Therapeutics | 75 |
Verastem | 73 |
Vigil Neuroscience | 69 |
Compugen | 68 |
Checkpoint Therapeutics | 23 |
Achieve Life Sciences | 22 |
ADVM News
- 6 hours ago - Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - GlobeNewsWire
- 19 days ago - Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - GlobeNewsWire
- 2 months ago - Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - GlobeNewsWire
- 3 months ago - Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 3 months ago - Adverum Biotechnologies, Inc's (ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Transcript - Seeking Alpha
- 3 months ago - Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting - GlobeNewsWire
- 6 months ago - Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - GlobeNewsWire